A new antiviral drug has been reported in a study that researchers believe has high clinical potential as a next-generation influenza drug.
List view / Grid view
Filter the results
Whole exome sequencing has been used by researchers to reveal 10 genes implicated in the development of schizophrenia.
Researchers have used whole genome sequencing to analyse breast cancers and reveal which are more responsive to treatments, which could improve the development of oncologic therapies.
The systematic successful treatment of cancer still eludes us and in an effort to refine this area of targeted medicine, Lauri Paasonen and colleagues explore the potential of using patient-derived cells (PDCs) for devising a personalised treatment strategy for solid tumours.
Having worked in antibody research for over 20 years, Gary McLean has seen how the industry has progressed and understands the potential that antibodies have in the future of medicine. Nikki Withers hears how the focus has shifted from discovery to genetic sequence manipulation and how this can be applied…
Whitepaper: Evaluating the impact of error rate on productivity and cost savings in synthetic DNA fragments
GeneArt High-Q Strings DNA Fragments versus other suppliers’ products.
This issue includes an investigation into utilising recombinant antibodies for research, a highlight on protein design using computational methods and an examination of the advances in genomic medicine. Also in the issue are articles on next generation sequencing and upstream bioprocessing.
A potential target for ALS has been revealed by a study which found the Fos-B gene encouraged axonal branching.
A team from MIT sequenced bacteria samples from the digestive system which can be accessed by researchers to use in the development of treatments.
A study has discovered a molecule key in neuronal growth that could be used as a drug target to treat anxiety-related diseases.
A new study has revealed that glioblastomas contain four different types of cell which the researchers say should be treated separately.
Unique considerations surrounding the bureaucracy and oversight in the use of human biospecimens in the European Union.
High content data derived for complex immuno-oncology research facilitates a deeper understanding of the tissue microenvironment.